Hashem M, El-Kassas M. Diagnosis, treatment protocols, and outcomes of liver transplant recipients infected with COVID-19. World J Clin Cases 2023; 11(10): 2140-2159 [PMID: 37122505 DOI: 10.12998/wjcc.v11.i10.2140]
Corresponding Author of This Article
Mohamed El-Kassas, MD, Professor, Department of Endemic Medicine, Faculty of Medicine, Helwan University, Ain Helwan, Cairo 11795, Egypt. m_elkassas@hq.helwan.edu.eg
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Apr 6, 2023; 11(10): 2140-2159 Published online Apr 6, 2023. doi: 10.12998/wjcc.v11.i10.2140
Diagnosis, treatment protocols, and outcomes of liver transplant recipients infected with COVID-19
Mai Hashem, Mohamed El-Kassas
Mai Hashem, Fellow of Tropical Medicine and Gastroenterology, Assiut University Hospital, Assiut 71515, Egypt
Mohamed El-Kassas, Department of Endemic Medicine, Faculty of Medicine, Helwan University, Cairo 11795, Egypt
Author contributions: Hashem M, and El-Kassas M contributed to the conception and design of the work, literature review, drafting and critical revision, editing, and approval of the final version of the manuscript.
Conflict-of-interest statement: The authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mohamed El-Kassas, MD, Professor, Department of Endemic Medicine, Faculty of Medicine, Helwan University, Ain Helwan, Cairo 11795, Egypt. m_elkassas@hq.helwan.edu.eg
Received: September 2, 2022 Peer-review started: September 2, 2022 First decision: January 5, 2023 Revised: January 20, 2023 Accepted: March 9, 2023 Article in press: March 9, 2023 Published online: April 6, 2023 Processing time: 208 Days and 21.9 Hours
Core Tip
Core Tip: Liver transplant (LT) patients infected with severe acute respiratory syndrome coronavirus 2 have clinical, biochemical, and radiological features highly comparable to those of immunocompetent patients, except for a higher incidence of gastrointestinal symptoms. The prognosis of LT recipients is similar to non-LT patients and is not significantly affected by immunosuppression but rather by comorbidities. Considering the risk of organ rejection, it may not be wise to stop all immunosuppression after a coronavirus disease 2019 diagnosis. All LT recipients should be vaccinated, considering booster doses augment vaccination immunogenicity. Still, a considerable proportion of patients remain at risk for coronavirus disease 2019. Therefore, social isolation and other precautions must be maintained.
